NZ601376A - Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors - Google Patents
Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitorsInfo
- Publication number
- NZ601376A NZ601376A NZ601376A NZ60137610A NZ601376A NZ 601376 A NZ601376 A NZ 601376A NZ 601376 A NZ601376 A NZ 601376A NZ 60137610 A NZ60137610 A NZ 60137610A NZ 601376 A NZ601376 A NZ 601376A
- Authority
- NZ
- New Zealand
- Prior art keywords
- indazol
- pyridine
- imidazo
- substituted
- carboxamide compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- AYAOSDNSSUARDZ-UHFFFAOYSA-N n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide Chemical class C1=CC=CN2C(C(NC=3C=4C=NNC=4C=CC=3)=O)=CN=C21 AYAOSDNSSUARDZ-UHFFFAOYSA-N 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28872909P | 2009-12-21 | 2009-12-21 | |
| PCT/US2010/061341 WO2011079076A1 (en) | 2009-12-21 | 2010-12-20 | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601376A true NZ601376A (en) | 2014-03-28 |
Family
ID=43568700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601376A NZ601376A (en) | 2009-12-21 | 2010-12-20 | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8841455B2 (enExample) |
| EP (1) | EP2516433B1 (enExample) |
| JP (2) | JP5739448B2 (enExample) |
| KR (1) | KR101779630B1 (enExample) |
| CN (1) | CN102822170B (enExample) |
| AR (1) | AR079541A1 (enExample) |
| AU (1) | AU2010333752B2 (enExample) |
| BR (1) | BR112012017123B1 (enExample) |
| CA (1) | CA2785338C (enExample) |
| CL (1) | CL2012001699A1 (enExample) |
| CO (1) | CO6561821A2 (enExample) |
| CR (1) | CR20120389A (enExample) |
| DK (1) | DK2516433T3 (enExample) |
| ES (1) | ES2494590T3 (enExample) |
| HR (1) | HRP20140770T1 (enExample) |
| IL (1) | IL220544A (enExample) |
| ME (1) | ME01894B (enExample) |
| MX (1) | MX2012007329A (enExample) |
| MY (1) | MY163791A (enExample) |
| NZ (1) | NZ601376A (enExample) |
| PL (1) | PL2516433T3 (enExample) |
| PT (1) | PT2516433E (enExample) |
| RS (1) | RS53500B1 (enExample) |
| RU (1) | RU2562977C2 (enExample) |
| SG (1) | SG181861A1 (enExample) |
| SI (1) | SI2516433T1 (enExample) |
| SM (1) | SMT201400142B (enExample) |
| TW (1) | TWI471326B (enExample) |
| UA (1) | UA108222C2 (enExample) |
| WO (1) | WO2011079076A1 (enExample) |
| ZA (1) | ZA201205505B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011019651A1 (en) | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| ES2652287T3 (es) | 2009-12-21 | 2018-02-01 | Samumed, Llc | 1H-pirazol [3,4-b] piridinas y usos terapéuticos de las mismas |
| HRP20140770T1 (hr) * | 2009-12-21 | 2014-11-07 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDA KAO INHIBITORI CFMS |
| KR101974665B1 (ko) | 2010-12-13 | 2019-05-02 | 어레이 바이오파마 인크. | 제ＩＩＩ형 수용체 티로신 키나제 억제제로서의 치환된 Ｎ-（１Ｈ-인다졸-４-일)이미다조［１,２-ａ］피리딘-３-카복스아마이드 화합물 |
| PL2755483T3 (pl) | 2011-09-14 | 2019-06-28 | Samumed, Llc | Indazolo-3-karboksyamidy i ich zastosowanie jako inhibitorów szlaków sygnalizacji WNT/B-kateniny |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US9309284B2 (en) | 2012-05-02 | 2016-04-12 | Kansas State University Reasearch Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses |
| MA37577B1 (fr) | 2012-05-04 | 2018-05-31 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
| US9908867B2 (en) | 2013-01-08 | 2018-03-06 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof |
| KR101756934B1 (ko) | 2014-07-08 | 2017-07-12 | 연세대학교 산학협력단 | 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물 |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| EA201791421A1 (ru) | 2014-12-22 | 2017-10-31 | Файв Прайм Терапьютикс, Инк. | Антитела против csf1r для лечения pvns |
| CN204833440U (zh) | 2015-07-29 | 2015-12-02 | 山东新北洋信息技术股份有限公司 | 识读组件及纸币清分机 |
| US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| WO2017023996A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| MX389958B (es) | 2015-11-06 | 2025-03-20 | Samumed Llc | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| MY199242A (en) | 2016-06-01 | 2023-10-22 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| WO2018075858A1 (en) | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| EP3535243B1 (en) | 2016-11-04 | 2021-12-15 | Auckland Uniservices Limited | Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| MX2019014021A (es) * | 2017-05-24 | 2020-08-17 | Abbisko Therapeutics Co Ltd | Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. |
| CN118748993A (zh) | 2021-12-28 | 2024-10-08 | 日本新药株式会社 | 吲唑化合物和药物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952101A (en) | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| AU2001264932A1 (en) * | 2000-05-26 | 2001-12-11 | Neurogen Corporation | Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands |
| JP4804480B2 (ja) | 2005-01-26 | 2011-11-02 | シェーリング コーポレイション | 癌の処置のためのプロテインキナーゼインヒビターとしての、３−（インダゾール−５−イル）−（１，２，４）トリアジン誘導体、および関連する化合物 |
| US7846941B2 (en) * | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
| ES2339480T3 (es) | 2005-06-24 | 2010-05-20 | Eli Lilly And Company | Derivados de tetrahidrocarbazol utiles como moduladores del receptor de androgenos (sarm). |
| CA2629342A1 (en) | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| NZ580327A (en) * | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| WO2009071483A1 (en) | 2007-12-07 | 2009-06-11 | Via Pharmaceuticals, Inc. | 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| WO2009147189A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| HRP20140770T1 (hr) * | 2009-12-21 | 2014-11-07 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDA KAO INHIBITORI CFMS |
| KR101974665B1 (ko) * | 2010-12-13 | 2019-05-02 | 어레이 바이오파마 인크. | 제ＩＩＩ형 수용체 티로신 키나제 억제제로서의 치환된 Ｎ-（１Ｈ-인다졸-４-일)이미다조［１,２-ａ］피리딘-３-카복스아마이드 화합물 |
-
2010
- 2010-12-20 HR HRP20140770AT patent/HRP20140770T1/hr unknown
- 2010-12-20 BR BR112012017123-2A patent/BR112012017123B1/pt not_active IP Right Cessation
- 2010-12-20 AR ARP100104761A patent/AR079541A1/es active IP Right Grant
- 2010-12-20 SI SI201030706T patent/SI2516433T1/sl unknown
- 2010-12-20 PL PL10798683T patent/PL2516433T3/pl unknown
- 2010-12-20 PT PT107986838T patent/PT2516433E/pt unknown
- 2010-12-20 NZ NZ601376A patent/NZ601376A/en not_active IP Right Cessation
- 2010-12-20 WO PCT/US2010/061341 patent/WO2011079076A1/en not_active Ceased
- 2010-12-20 AU AU2010333752A patent/AU2010333752B2/en not_active Ceased
- 2010-12-20 KR KR1020127019199A patent/KR101779630B1/ko not_active Expired - Fee Related
- 2010-12-20 EP EP10798683.8A patent/EP2516433B1/en active Active
- 2010-12-20 MX MX2012007329A patent/MX2012007329A/es active IP Right Grant
- 2010-12-20 US US13/517,938 patent/US8841455B2/en active Active
- 2010-12-20 ME MEP-2014-99A patent/ME01894B/me unknown
- 2010-12-20 DK DK10798683.8T patent/DK2516433T3/da active
- 2010-12-20 MY MYPI2012002855A patent/MY163791A/en unknown
- 2010-12-20 SG SG2012046009A patent/SG181861A1/en unknown
- 2010-12-20 CN CN201080064462.XA patent/CN102822170B/zh not_active Expired - Fee Related
- 2010-12-20 CA CA2785338A patent/CA2785338C/en active Active
- 2010-12-20 UA UAA201208998A patent/UA108222C2/ru unknown
- 2010-12-20 RU RU2012131129/04A patent/RU2562977C2/ru active
- 2010-12-20 ES ES10798683.8T patent/ES2494590T3/es active Active
- 2010-12-20 JP JP2012546120A patent/JP5739448B2/ja not_active Expired - Fee Related
- 2010-12-20 RS RSP20140440 patent/RS53500B1/sr unknown
- 2010-12-21 TW TW99145074A patent/TWI471326B/zh not_active IP Right Cessation
-
2012
- 2012-06-21 CL CL2012001699A patent/CL2012001699A1/es unknown
- 2012-06-21 IL IL220544A patent/IL220544A/en active IP Right Grant
- 2012-07-19 CO CO12122160A patent/CO6561821A2/es unknown
- 2012-07-20 ZA ZA2012/05505A patent/ZA201205505B/en unknown
- 2012-07-20 CR CR20120389A patent/CR20120389A/es unknown
-
2014
- 2014-09-30 SM SM201400142T patent/SMT201400142B/xx unknown
-
2015
- 2015-01-22 JP JP2015010346A patent/JP2015107999A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601376A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors | |
| EA201290305A1 (ru) | Производные трициклического пиразоламина | |
| EA201270498A1 (ru) | 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс | |
| TN2012000559A1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| CR20130349A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
| MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
| MX2010008198A (es) | Inhibidores de cinasa de pirrolopirazina. | |
| MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
| MY160454A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| PL2250172T3 (pl) | Pirolopirazynowe inhibitory kinazy | |
| TW200942543A (en) | Pyrrolopyrazine kinase inhibitors | |
| PH12012502391A1 (en) | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | |
| WO2010151710A3 (en) | Substituted heterocyclic compounds as kinases inhibitors and method of use thereof | |
| MX2011011735A (es) | Compuestos y metodos para la inhibicion de renina, e indicaciones para ello. | |
| MX2012012614A (es) | Compuestos de 7-(1h-pirazol-4-il)-1, 6-naftiridina como inhibidores de syk. | |
| PT2470546E (pt) | Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor | |
| TN2011000293A1 (en) | Protein kinase inhibitors | |
| WO2011080568A8 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| TN2009000389A1 (en) | Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer | |
| WO2011079230A3 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| MX2010006331A (es) | Hidantoinas sustituidas como inhibidores de cinasa mek. | |
| UA96745C2 (en) | PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| PH12014501434A1 (en) | Quinoline derivatives as pde10a enzyme inhibitors | |
| EA201171030A1 (ru) | 2-МОРФОЛИНОПИРИДО[3,2-d]ПИРИМИДИНЫ | |
| MX2012006897A (es) | Compuestos heterociclicos como inhibidores de janus cinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2015 BY COMPUTER PACKAGES INC Effective date: 20141202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2016 BY COMPUTER PACKAGES INC Effective date: 20151201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2017 BY COMPUTER PACKAGES INC Effective date: 20161201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2018 BY COMPUTER PACKAGES INC Effective date: 20171201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2019 BY COMPUTER PACKAGES INC Effective date: 20181201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2020 BY COMPUTER PACKAGES INC Effective date: 20191203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2022 BY THOMSON REUTERS Effective date: 20211102 |
|
| LAPS | Patent lapsed |